{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ara+C&page=4", "query": { "intervention": "Ara C", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 905, "total_pages": 91, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ara+C&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ara+C&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-08T10:23:15.432Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03072771", "title": "Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diffuse Large B Cell Lymphoma" ], "interventions": [ { "name": "Blinatumomab", "type": "DRUG" }, { "name": "Autologous stem cell transplant", "type": "PROCEDURE" }, { "name": "Carmustine", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Peripheral blood draws", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2017-08-01", "completion_date": "2023-10-30", "has_results": false, "last_update_posted_date": "2023-11-28", "last_synced_at": "2026-10-08T10:23:15.432Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03072771" }, { "nct_id": "NCT04530565", "title": "Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Blinatumomab", "type": "BIOLOGICAL" }, { "name": "Bone Marrow Aspiration and Biopsy", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Electrocardiography", "type": "PROCEDURE" }, { "name": "Lumbar Puncture", "type": "PROCEDURE" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Ponatinib Hydrochloride", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 348, "start_date": "2021-01-25", "completion_date": "2028-07-01", "has_results": false, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-10-08T10:23:15.432Z", "location_count": 207, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fort Smith, Arkansas + 145 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04530565" }, { "nct_id": "NCT06007911", "title": "Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed Adult AML", "Refractory AML" ], "interventions": [ { "name": "Navitoclax Dose Level 1", "type": "DRUG" }, { "name": "Navitoclax Dose Level 0", "type": "DRUG" }, { "name": "Navitoclax Dose Level 2", "type": "DRUG" }, { "name": "Venetoclax Dose Level -1", "type": "DRUG" }, { "name": "Venetoclax Dose Levels 0 to 2", "type": "DRUG" }, { "name": "Cladribine", "type": "DRUG" }, { "name": "Cytarabine (Cladribine Low Dose Cytarabine Backbone)", "type": "DRUG" }, { "name": "Cytarabine (CLAG-M Backbone)", "type": "DRUG" }, { "name": "Mitoxantrone", "type": "DRUG" }, { "name": "Granulocyte Colony-Stimulating Factor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2024-08-31", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2024-08-13", "last_synced_at": "2026-10-08T10:23:15.432Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT06007911" }, { "nct_id": "NCT01614197", "title": "A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoblastic Leukemia, Acute, Childhood", "Lymphoblastic Lymphoma", "Peripheral T-cell Lymphoma" ], "interventions": [ { "name": "Temsirolimus", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Hydrocortisone", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Therapeutic Advances in Childhood Leukemia Consortium", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 16, "start_date": "2015-07-03", "completion_date": "2020-09-04", "has_results": true, "last_update_posted_date": "2023-07-27", "last_synced_at": "2026-10-08T10:23:15.432Z", "location_count": 25, "location_summary": "Los Angeles, California • Orange, California • San Francisco, California + 22 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01614197" }, { "nct_id": "NCT03808610", "title": "Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent B Acute Lymphoblastic Leukemia", "Recurrent T Acute Lymphoblastic Leukemia", "Refractory B Acute Lymphoblastic Leukemia", "Refractory T Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Nelarabine", "type": "DRUG" }, { "name": "Pegaspargase", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2019-04-03", "completion_date": "2026-05-05", "has_results": false, "last_update_posted_date": "2026-05-13", "last_synced_at": "2026-10-08T10:23:15.432Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03808610" }, { "nct_id": "NCT02342782", "title": "Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma", "Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma", "Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma", "Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma", "Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Yttrium Y 90 Basiliximab", "type": "BIOLOGICAL" }, { "name": "Carmustine", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Autologous Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2020-06-08", "completion_date": "2024-11-18", "has_results": false, "last_update_posted_date": "2025-03-20", "last_synced_at": "2026-10-08T10:23:15.432Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02342782" }, { "nct_id": "NCT07014462", "title": "A Phase 1B Investigator Initiated Study of Safety and Tolerability of Dexamethasone (D) in Combination With Venetoclax-based Low-Intensity Therapy (LIT) in Treatment-Naïve Acute Myeloid Leukemia (AML): DLIT-AML", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "AML - Acute Myeloid Leukemia" ], "interventions": [ { "name": "Dexamethasone plus Venetoclax-based Low-Intensity Therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Vermont", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2025-09-01", "completion_date": "2029-06", "has_results": false, "last_update_posted_date": "2025-10-06", "last_synced_at": "2026-10-08T10:23:15.432Z", "location_count": 1, "location_summary": "Burlington, Vermont", "locations": [ { "city": "Burlington", "state": "Vermont" } ], "official_url": "https://clinicaltrials.gov/study/NCT07014462" }, { "nct_id": "NCT00774046", "title": "High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AML", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelodysplastic Syndrome", "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Ara-C", "type": "DRUG" }, { "name": "Mitoxantrone", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": null, "sex": "ALL", "summary": "10 Years and older" }, "enrollment_count": 32, "start_date": "2002-12", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2014-02-11", "last_synced_at": "2026-10-08T10:23:15.432Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00774046" }, { "nct_id": "NCT02676323", "title": "Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia", "Myelodysplastic Syndrome" ], "interventions": [ { "name": "Panobinostat", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Intrathecal Triples", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "24 Years", "sex": "ALL", "summary": "Up to 24 Years" }, "enrollment_count": 19, "start_date": "2016-05-03", "completion_date": "2018-04-09", "has_results": false, "last_update_posted_date": "2018-11-14", "last_synced_at": "2026-10-08T10:23:15.432Z", "location_count": 7, "location_summary": "Los Angeles, California • Palo Alto, California • San Diego, California + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02676323" }, { "nct_id": "NCT06895473", "title": "Intrathecal Cytarabine, Methotrexate, and Hydrocortisone for the Prevention of High-Grade Chimeric Antigen Receptor T-Cell-Associated Neurotoxicity Syndrome", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hematopoietic and Lymphatic System Neoplasm" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Lumbar Puncture", "type": "PROCEDURE" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Therapeutic Hydrocortisone", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2025-06-04", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-06-26", "last_synced_at": "2026-10-08T10:23:15.432Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT06895473" } ] }